NCT01351948View on ClinicalTrials.gov

Safety and Immunogenicity of Malaria Vaccines AdCh63 AMA1, MVA AMA1 and AMA1-C1/Alhydrogel®+/- CPG 7909

PHASE1CompletedINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

June 30, 2011

Primary Completion Date

March 31, 2013

Study Completion Date

March 31, 2013

Conditions
Malaria
Interventions
BIOLOGICAL

AdCh63 AMA1 + MVA AMA1 + AMA1-C1/Alhydrogel®+ CPG 7909

5x10\^10 vp AdCh63 AMA1 Day 0, 1.25x10\^8 pfu MVA AMA1 Day 56, AMA1-C1/Alhydrogel®+ CPG 7909 (80ug, 800ug, 564ug respectively) Day 112. IM injections

BIOLOGICAL

AdCh63 AMA1 + AMA1-C1/Alhydrogel®+ CPG 7909

5x10\^10 vp AdCh63 AMA1 Day 0,AMA1-C1/Alhydrogel®+ CPG 7909 (80ug, 800ug, 564ug respectively) Day 56. IM injections

BIOLOGICAL

AdCh63 AMA1 + AMA1-C1/Alhydrogel®

5x10\^10 vp AdCh63 AMA1 Day 0, AMA1-C1/Alhydrogel® (80ug, 800ug respectively) Day 56. IM injections

BIOLOGICAL

AdCh63 AMA1 AMA1-C1/Alhydrogel®+ CPG 7909

5x10\^10 vp AdCh63 AMA1 Day 0, AMA1-C1/Alhydrogel®+ CPG 7909 (80ug, 800ug, 564ug respectively) Day 112. IM injections

BIOLOGICAL

AdCh63 AMA1 + MVA AMA1

5x10\^10 vp AdCh63 AMA1 Day 0, 1.25x10\^8 pfu MVA AMA1 Day 112. IM injections

Trial Locations (1)

OX3 7LJ

Centre for Clinical Vaccinology and Tropical Medicine, Churchill Hospital, Old Road, Headington, Oxford

All Listed Sponsors
collaborator

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

lead

University of Oxford

OTHER

NCT01351948 - Safety and Immunogenicity of Malaria Vaccines AdCh63 AMA1, MVA AMA1 and AMA1-C1/Alhydrogel®+/- CPG 7909 | Biotech Hunter | Biotech Hunter